WO2019203746A3 - Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole - Google Patents

Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole Download PDF

Info

Publication number
WO2019203746A3
WO2019203746A3 PCT/TR2018/050772 TR2018050772W WO2019203746A3 WO 2019203746 A3 WO2019203746 A3 WO 2019203746A3 TR 2018050772 W TR2018050772 W TR 2018050772W WO 2019203746 A3 WO2019203746 A3 WO 2019203746A3
Authority
WO
WIPO (PCT)
Prior art keywords
aripiprazole
raloxifene
pharmaceutical combination
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050772
Other languages
English (en)
Other versions
WO2019203746A2 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DÖNMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2019203746A2 publication Critical patent/WO2019203746A2/fr
Publication of WO2019203746A3 publication Critical patent/WO2019203746A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une combinaison qui comprend du raloxifène ou un sel pharmaceutiquement acceptable de celui-ci et de l'aripiprazole ou un sel pharmaceutiquement acceptable de celui-ci et éventuellement au moins un excipient pharmaceutiquement acceptable pour une utilisation simultanée, séparée ou séquentielle.
PCT/TR2018/050772 2017-12-08 2018-12-06 Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole Ceased WO2019203746A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/19919A TR201719919A2 (tr) 2017-12-08 2017-12-08 The pharmaceutical combination comprising raloxifene and aripiprazole
TR2017/19919 2017-12-08

Publications (2)

Publication Number Publication Date
WO2019203746A2 WO2019203746A2 (fr) 2019-10-24
WO2019203746A3 true WO2019203746A3 (fr) 2020-01-16

Family

ID=67952525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050772 Ceased WO2019203746A2 (fr) 2017-12-08 2018-12-06 Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole

Country Status (2)

Country Link
TR (1) TR201719919A2 (fr)
WO (1) WO2019203746A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
WO2015082562A1 (fr) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Procédé de production de formulations médicamenteuses pour une administration par voie orale
WO2017149392A1 (fr) * 2016-03-04 2017-09-08 Sharon Anavi-Goffer Compositions auto-émulsifiantes de modulateurs du récepteur cb2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
WO2015082562A1 (fr) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Procédé de production de formulations médicamenteuses pour une administration par voie orale
WO2017149392A1 (fr) * 2016-03-04 2017-09-08 Sharon Anavi-Goffer Compositions auto-émulsifiantes de modulateurs du récepteur cb2

Also Published As

Publication number Publication date
TR201719919A2 (tr) 2019-06-21
WO2019203746A2 (fr) 2019-10-24

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12019501076A1 (en) Pharmaceutical formulations
MX2017016802A (es) Formulaciones farmaceuticas.
PH12016501841A1 (en) Immunosuppressant formulation
MX2020012989A (es) Agente terapeutico para la fibrosis.
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
EP4062938A4 (fr) Association médicamenteuse
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
EP4467138A3 (fr) Agents thérapeutiques pour maladies neurodégénératives
TR201715231A2 (tr) Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
IN2013MU03370A (fr)
WO2019203748A3 (fr) Combinaison comprenant du raloxifène et au moins un agent antipsychotique
WO2019203746A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole
PL3996688T3 (pl) Preparat farmaceutyczny
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine
HK1254687A1 (zh) 用於癌症的联合疗法
WO2019203747A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique
WO2020139238A3 (fr) Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique
HK40039345A (en) New pharmaceutical use
GB201917327D0 (en) New pharmaceutical use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18915220

Country of ref document: EP

Kind code of ref document: A2